Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. vice president and chief accounting officer Heather Howlett reported several equity-compensation transactions. On March 2, 2026, she received a grant of 22,233 Restricted Stock Units that correspond 1-for-1 with Kenvue common stock and vest in three equal installments on March 2 of 2027, 2028, and 2029, subject to continued service. On March 3, 2026, 1,534.48 Restricted Stock Units were converted into the same number of common shares, and 526 shares of common stock were withheld at $18.15 per share to cover taxes upon vesting. After these transactions, she directly owned 31,198.5 shares of common stock.
Kenvue Inc. reported that Group President EMEA & LA Lawson Carlton acquired a grant of 93,488 restricted stock units. These RSUs carry no purchase price and correspond on a one-for-one basis with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, conditioned on Carlton’s continued service through each vesting date. This filing reflects equity-based compensation rather than an open-market share purchase or sale.
Kenvue Inc. reported that Chief People Officer Luani Alvarado acquired 79,407 Restricted Stock Units as a grant. Each unit corresponds 1-for-1 with Kenvue common stock and was awarded at no cash cost. The award vests in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, contingent on continued service through each vesting date. Following this grant, Alvarado directly holds 79,407 restricted stock units.
Kenvue Inc. reported that Group President North America Carlos De Jesus acquired 127,051 restricted stock units (RSUs) on March 2, 2026 as an equity award. Each RSU corresponds one-for-one with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on his continued service with the company.
Perry Kirk reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. reported that Chief Executive Officer Perry Kirk received a grant of 491,662 restricted stock units that correspond one-for-one with Kenvue common stock. The award was granted on 03/02/2026 and will vest in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, subject to his continued service with the company.
Kenvue Inc. reported that Chief Scientific Officer Caroline Tillett acquired 63,525 Restricted Stock Units as an equity award. The units were granted at no cash cost and correspond one-for-one with Kenvue common stock.
This award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, as long as Tillett continues to serve at the company through each vesting date. All 63,525 RSUs are currently reported as directly owned following the grant.
Stevens Meredith reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. Chief Operations Officer Meredith Stevens received a grant of 92,641 restricted stock units that correspond 1-for-1 with Kenvue common stock. The award was granted as of 03/02/2026 and will vest in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, subject to her continued service.
Kenvue Inc. reported that Chief Digital & Marketing Officer Jonathan Halvorson acquired 51,879 restricted stock units as a compensation award. The units were granted at no cash cost and correspond one-for-one with Kenvue common stock. The award vests in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, conditioned on his continued service with the company.
Kenvue Inc. reported that Chief Corp. Affairs Officer Russell Dyer acquired a grant of 43,673 restricted stock units (RSUs), each corresponding 1-for-1 with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on his continued service through each vesting date.
Kenvue Inc. files its annual report describing a global consumer health business built on iconic brands and a major pending merger.
The company reports $15.1 billion in Net sales in fiscal 2025, positioning it as the world’s largest pure-play consumer health company by revenue. It operates three segments—Self Care, Skin Health and Beauty, and Essential Health—across more than 165 countries, supported by a sizable in-house and third‑party manufacturing and distribution network.
The filing details Kenvue’s post‑separation evolution from Johnson & Johnson, its extensive regulatory environment, sustainability and human‑capital strategies, and a proposed combination with Kimberly‑Clark. Shareholders of both firms have approved the merger, which still requires additional foreign regulatory clearances and other customary conditions.